Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality

Prouet, Philippe; Giri, Smith; Wiedower, Eric; Fintel, Andrew; Yaghmour, George; Lamb, Elena P; Deneve, Jeremiah L.; Fleming, Martin D.; Dickson, Paxton V.; Chandler, Jason C.; Martin, Michael

doi:10.21873/anticanres.11382

Cited by 6 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no specific prognostic factors have been identified including the International Prognostic Index (IPI), because most patients were at low-or low-intermediate clinical risk and will be considered as low risk; other factors such as deep of invasion, tumor burden, lymph node invasion, and molecular profile have not been validated. [4][5][6][7][8][9][10][11][12][13][14][15] The use of combined treatments such as surgery, radiotherapy, and chemotherapy did not show any benefit in this setting of patients, [3][4][5][6][7][8][9][10][11] and the addition of rituximab is controversial; 4,5 in our experience, the addition of rituximab to CHOP chemotherapy does not improve outcome. 16 Some years ago, we performed a retrospective clinical study and found that patients with elevated serum levels of lactic dehydrogenase (LDH) and beta 2 microglobulin (B2M) (>2 of normal levels) have a worse prognosis, independent of other prognostic factors.…”

Section: Introductionmentioning

confidence: 85%

Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy

Avilés

Nambo

Neri

2018

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective To assess if the use of a dose-dense regimen of chemotherapy can improve the prognosis in patients with primary gastric diffuse large B-cell lymphoma in early stages (I–II) but associated with worse prognostic factors. Methods One hundred and eight consecutive patients with primary gastric diffuse large B-cell lymphoma in early stages (I–II) with high serum levels of lactic dehydrogenase and beta 2 microglobulin (more than >2 of normal levels), which were associated with a worse prognostic outcome, were treated with a dose-dense chemotherapy: CHOP with increased doses of cyclophosphamide and doxorubicin, was administered every 14 days (instead of 21 days). The end points of this study were to improve outcome measured from progression-free survival and overall survival and to evaluate acute toxicities. Results Complete response was achieved in 85 patients (78%). Actuarial curves at five years show that progression-free survival was 82% and overall survival was 85%. Hematological toxicities were severe, but no death-related treatment was observed. Conclusions We considered that in this setting of patients, the use of a dose-dense regimen could be of benefit because it improves outcome and toxicities were well controlled.

show abstract

Section: Introductionmentioning

confidence: 85%

Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy

Avilés

Nambo

Neri

2018

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…23 Current studies have confirmed that the presence of Rituximab reduces the surgical rate of PG-DLBCL and do not increase the early mortality. 24 However, a SEER-based study of PG-DLBCL suggested that patient age, tumor stage, chemotherapy, and surgery were independent risk factors for long-term survival of PG-DLBCL patients, at the same time, the risk of death was high in the first two years, during which active follow-up should be pursued. 6 In our study, Chemotherapy and surgery are beneficial for overall survival of PsI-DLBCL, the internal validation based on SEER is also consistent.…”

Section: Discussionmentioning

confidence: 99%

Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma

Liu¹,

Cao²,

Liu³

et al. 2022

CMAR

View full text Add to dashboard Cite

This study aimed to analyze the clinical features and survival of primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL), and establish and independently validate a prognostic nomogram for individual risk prediction. Patients and methods: Data for 24 patients from the Renmin Hospital of Wuhan University were used as an independent validation cohort, data for 1144 patients with PsI-DLBCL from the SEER database were randomly assigned to training (N=817) and internal validation (N=327) sets. The survival nomogram was constructed with the most significant factors associated with OS using Univariate and multivariate analyses on the training set. Decision curve analysis (DCA) was conducted. Internal validation was SEER validation set. Our cancer center cohort was used as an external validation set to further verify the survival nomogram. Results: Five clinicopathological feature factors associated with OS of the training set yielded (age, marital status, Ann Arbor stage, surgery for primary site and chemotherapy), which were used to create a survival nomogram. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. The stability of our survival nomogram was explained by internal and external validation data. Conclusion: Our nomogram proposes the clinical and therapeutic factors affecting OS for patients with PsI-DLBCL. It shows that chemotherapy and surgery are beneficial to patients in the choice of treatment options. These results suggest that a survival nomogram may be better at predicting OS for PsI-DLBCL patients.

show abstract

“…The year of diagnosis was divided by decade 29 . The reason why we chose patients diagnosed from 1983 to 2015 was that they had complete Ann Arbor staging and surgical information 30 . Staging was defined according to Ann Arbor Stage of lymphoma.…”

Section: Methodsmentioning

confidence: 99%

The impact of surgery on long-term survival of patients with primary intestinal non-Hodgkin lymphomas based on SEER database

Zhang

Liu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Evidence regarding the need for surgery for primary intestinal non-Hodgkin lymphoma (PINHL) patients with chemotherapy is limited and controversial. We aimed to investigate the specific impact of surgery on survival of PINHL patients. Data from PINHL patients (aged > 18 years) with chemotherapy between 1983 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We concerned about overall survival (OS) and improved cancer-specific survival (CSS). Propensity score matching (PSM) analysis was also used to explore the reliability of the results to further control for confounding factors. Finally, we screened 3537 patients. Multivariate regression analysis showed that patients with surgery and chemotherapy had better OS (hazard ratio [HR] 0.83; 95% confidence interval [CI] 0.75–0.93; p = 0.0009) and CSS (HR 0.87; 95% CI 0.77–0.99; p = 0.0404) compared with the non-operation group after adjusting for confounding factors. After PSM analysis, compared with non-surgery, surgery remained associated with improved OS (HR 0.77; 95% CI 0.68–0.87; p < 0.0001) and improved CSS (HR 0.82; 95% CI 0.72–0.95; p = 0.008) adjusted for baseline differences. In the large cohort of PINHL patients with chemotherapy older than 18 years, surgery was associated with significantly improved OS and CSS before and after PSM analysis.

show abstract

Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality

Abstract: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.

Cited by 6 publications

References 8 publications

Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy

Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy

Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma

The impact of surgery on long-term survival of patients with primary intestinal non-Hodgkin lymphomas based on SEER database

Contact Info

Product

Resources

About